KRAS and colorectal carcinoma: Moreover, RMC-4630 is being tested in combination with the MEK inhibitor cobimetinib, which has shown some preliminary evidence of antitumour activity in KRAS-mutated CRC, as indicated by tumour reduction in 37.5% of patients (three of eight).